Cirrus HD-OCT (Carl Zeiss Meditec Inc.) for diagnosis of glaucoma

Record ID 32013000220
English
Authors' recommendations: Glaucoma describes a group of eye diseases characterized by damage to the optic nerve, leading to irreversible vision loss and blindness. Glaucoma affects more than 60 million people worldwide and approximately 2.2 million people in the United States. Glaucoma usually begins with subtle loss of peripheral vision and, if left undiagnosed and untreated, will eventually progress to complete blindness. Because the visual impairment from glaucoma is irreversible, early detection of the disease is important. The retinal nerve fiber layer (RNFL) thickness, formed by the expansion of the fibers of the optic nerve, is a valuable parameter in the diagnosis and follow-up of glaucoma. Optical coherence tomography (OCT) is a technology developed to objectively measure the thickness of the RNFL in a noninvasive manner. Standard time-domain OCT is typically performed with the Stratus OCT device manufactured by Carl Zeiss Meditec Inc. A newer technology from the same manufacturer, the Cirrus high-definition (HD) OCT, is a spectral-domain OCT instrument.
Details
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Reproducibility of Results
  • Tomography, Optical Coherence
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.